ES2231277T3 - Un nuevo uso de levosimendano. - Google Patents
Un nuevo uso de levosimendano.Info
- Publication number
- ES2231277T3 ES2231277T3 ES00969616T ES00969616T ES2231277T3 ES 2231277 T3 ES2231277 T3 ES 2231277T3 ES 00969616 T ES00969616 T ES 00969616T ES 00969616 T ES00969616 T ES 00969616T ES 2231277 T3 ES2231277 T3 ES 2231277T3
- Authority
- ES
- Spain
- Prior art keywords
- levosimendano
- treatment
- sinus
- patient
- sinoatrial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010040639 Sick sinus syndrome Diseases 0.000 claims abstract description 9
- 208000014526 Conduction disease Diseases 0.000 claims abstract description 6
- WHXMKTBCFHIYNQ-UHFFFAOYSA-N 2-[[4-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]hydrazinylidene]propanedinitrile Chemical compound CC1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-UHFFFAOYSA-N 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 abstract description 3
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 abstract description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 229960000692 levosimendan Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 11
- 239000002775 capsule Substances 0.000 description 7
- 210000001013 sinoatrial node Anatomy 0.000 description 6
- 239000000969 carrier Substances 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001990 intravenous administration Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 description 4
- 229960003574 milrinone Drugs 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010063836 Atrioventricular septal defect Diseases 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000001992 atrioventricular node Anatomy 0.000 description 2
- 208000006218 bradycardia Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 210000005245 right atrium Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010029470 Nodal rhythm Diseases 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000028922 artery disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 201000002934 first-degree atrioventricular block Diseases 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI992298 | 1999-10-22 | ||
| FI992298 | 1999-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2231277T3 true ES2231277T3 (es) | 2005-05-16 |
Family
ID=8555494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00969616T Expired - Lifetime ES2231277T3 (es) | 1999-10-22 | 2000-10-20 | Un nuevo uso de levosimendano. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6911209B1 (enExample) |
| EP (1) | EP1248620B1 (enExample) |
| JP (1) | JP2003512328A (enExample) |
| AT (1) | ATE282414T1 (enExample) |
| AU (1) | AU7928700A (enExample) |
| CA (1) | CA2387920C (enExample) |
| DE (1) | DE60016038T2 (enExample) |
| ES (1) | ES2231277T3 (enExample) |
| WO (1) | WO2001028560A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9132275B2 (en) | 2010-11-18 | 2015-09-15 | Cardiac Pacemakers, Inc. | Automatic determination of chronotropic incompetence using atrial pacing at rest |
| US11969424B2 (en) | 2019-12-16 | 2024-04-30 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8722776D0 (en) * | 1987-09-28 | 1987-11-04 | Smith Kline French Lab | Chemical compounds |
| GB2251615B (en) | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| GB2266841A (en) | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
| US5969017A (en) | 1996-10-31 | 1999-10-19 | Merck & Co., Inc. | Methods of treating or preventing cardiac arrhythmia |
-
2000
- 2000-10-20 ES ES00969616T patent/ES2231277T3/es not_active Expired - Lifetime
- 2000-10-20 JP JP2001531390A patent/JP2003512328A/ja active Pending
- 2000-10-20 CA CA002387920A patent/CA2387920C/en not_active Expired - Fee Related
- 2000-10-20 AT AT00969616T patent/ATE282414T1/de not_active IP Right Cessation
- 2000-10-20 EP EP00969616A patent/EP1248620B1/en not_active Expired - Lifetime
- 2000-10-20 US US10/111,099 patent/US6911209B1/en not_active Expired - Fee Related
- 2000-10-20 AU AU79287/00A patent/AU7928700A/en not_active Abandoned
- 2000-10-20 WO PCT/FI2000/000915 patent/WO2001028560A1/en not_active Ceased
- 2000-10-20 DE DE60016038T patent/DE60016038T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2387920A1 (en) | 2001-04-26 |
| JP2003512328A (ja) | 2003-04-02 |
| WO2001028560A1 (en) | 2001-04-26 |
| DE60016038T2 (de) | 2005-12-22 |
| US6911209B1 (en) | 2005-06-28 |
| AU7928700A (en) | 2001-04-30 |
| CA2387920C (en) | 2008-08-26 |
| EP1248620B1 (en) | 2004-11-17 |
| DE60016038D1 (de) | 2004-12-23 |
| EP1248620A1 (en) | 2002-10-16 |
| ATE282414T1 (de) | 2004-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kantor et al. | Imipramine-Induced Heart Block A Longitudinal Case Study | |
| KR101653071B1 (ko) | 선별적 ｓ1ｐ₁ 수용체 작동약에 대한 투약 섭생 | |
| Heiman et al. | Suppression of ventricular arrhythmias by transvenous intracardiac pacing | |
| Pollick et al. | The cardiac effects of d-and l-disopyramide in normal subjects: a noninvasive study. | |
| Zipes et al. | Aprindine for treatment of supraventricular tachycardias: With particular application to Wolff-Parkinson-White syndrome | |
| Cohen et al. | Treatment of supraventricular tachycardias with catheter and permanent pacemakers | |
| Beermann et al. | Advanced heart block aggravated by carbamazepine. | |
| Shah et al. | Atropine resistant post infarction complete AV block: possible role of adenosine and improvement with aminophylline | |
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| JPS61145121A (ja) | ジペプタイド誘導体を含有する、筋萎縮性側索硬化症を治療するための薬剤 | |
| JPS59112948A (ja) | コレステロ−ルレベル低下剤 | |
| Waagstein et al. | Clinical results with prenalterol in patients with heart failure | |
| Beermann et al. | Depressive effects of carbamazepine on idioventricular rhythm in man | |
| ES2231277T3 (es) | Un nuevo uso de levosimendano. | |
| Yasue et al. | Acute myocardial infarction induced by ergotamine tartrate: possible role of coronary arterial spasm | |
| Cannom et al. | Clinical and induced ventricular tachycardia in a patient with myotonic dystrophy | |
| CA2335280C (en) | Method of treating pulmonary hypertension | |
| ES2240110T3 (es) | Un metodo para el tratamiento o prevencion del vasoespasmo de injerto coronado. | |
| Dimich et al. | Treatment of recurrent paroxysmal ventricular tachycardia | |
| Eggleston et al. | SOME NEWER CONCEPTS IN DIGITALIS THERAPY. | |
| Stevenson et al. | Torsades de pointes due to N‐acetylprocainamide | |
| JP2003512328A5 (enExample) | ||
| FUJIMOTO et al. | The effects of class IA antiarrhythmic drug on the common type of atrial flutter in combination with pacing therapy | |
| ES2225580T3 (es) | Un metodo para tratar el choque septico. | |
| Berkenboom et al. | Clinical and Hemodynamic Observations on Orally Administered Sulmazol (AR115BS) in Refractory Heart Failure |